Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema

Anti-vascular endothelial growth factor (VEGF) therapy has become the first-line choice for center-involved diabetic macular edema (DME) treatment.1 Currently, three anti-VEGF drugs are routinely used in DME treatment: bevacizumab (Avastin; Genentech, South San Francisco, CA), ranibizumab (Lucentis; Genentech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Of these, only ranibizumab and aflibercept have U.S. Food and Drug Administration (FDA) approval for the treatment of DME, whereas bevacizumab is used off-label.1 –4 Despite the efficacy of these drugs in the

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - September 14, 2017 Category: Opthalmology Authors: Touka Banaee, MD Source Type: research